Next Article in Journal
Inhibition of Bacterial RNase P RNA by Phenothiazine Derivatives
Next Article in Special Issue
The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation
Previous Article in Journal
Internalization of the Extracellular Full-Length Tau Inside Neuro2A and Cortical Cells Is Enhanced by Phosphorylation
Previous Article in Special Issue
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
Article Menu

Export Article

Open AccessArticle
Biomolecules 2016, 6(3), 37; doi:10.3390/biom6030037

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer

1
Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10065, USA
2
Institut National de la Santé et de la Recherche médicale (Inserm) Unit U955 Eq07, CHU Henri Mondor, Créteil 94010, France
3
Department of Urology, Medical University of Vienna, Vienna 1090, Austria
4
Canada’s Michael Smith Genome Sciences Center, Cancer Research Center, Vancouver, BC V5Z4S6, Canada
5
Institute of Cancer Research, Department of Medicine 1, Medical University of Vienna, Vienna 1090, Austria
6
Department of Pathology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10065, USA
7
Division of Physiology and Biophysics, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10065, USA
8
Division of Medical Oncology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10065, USA
9
Department of Urology, University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Jürg Bähler
Received: 21 June 2016 / Revised: 11 August 2016 / Accepted: 12 August 2016 / Published: 2 September 2016
(This article belongs to the Special Issue DNA Methylation and Cancer)
View Full-Text   |   Download PDF [2245 KB, uploaded 2 September 2016]   |  

Abstract

Bladder cancer is among the five most common cancers diagnosed in the Western world and causes significant mortality and morbidity rates in affected patients. Therapeutic options to treat the disease in advanced muscle-invasive bladder cancer (MIBC) include cystectomy and chemotherapy. Neoadjuvant cisplatin-based combination chemotherapy is effective in MIBC; however, it has not been widely adopted by the community. One reason is that many patients do not respond to neoadjuvant chemotherapy, and no biomarker currently exists to identify these patients. It is also not clear whether a strategy to sensitize chemoresistant patients may exist. We sought to identify cisplatin-resistance patterns in preclinical models of bladder cancer, and test whether treatment with the epigenetic modifier decitabine is able to sensitize cisplatin-resistant bladder cancer cell lines. Using a screening approach in cisplatin-resistant bladder cancer cell lines, we identified dysregulated genes by RNA sequencing (RNAseq) and DNA methylation assays. DNA methylation analysis of tumors from 18 patients receiving cisplatin-based chemotherapy was used to confirm in vitro results. Cisplatin-resistant bladder cancer cells were treated with decitabine to investigate epigenetic sensitization of resistant cell lines. Our results show that HOXA9 promoter methylation status is associated with response to cisplatin-based chemotherapy in bladder cancer cell lines and in metastatic bladder cancer. Bladder cancer cells resistant to cisplatin chemotherapy can be sensitized to cisplatin by the DNA methylation inhibitor decitabine. Our data suggest that HOXA9 promoter methylation could serve as potential predictive biomarker and decitabine might sensitize resistant tumors in patients receiving cisplatin-based chemotherapy. View Full-Text
Keywords: HOXA9; urinary bladder neoplasms; drug resistance; neoadjuvant therapy; decitabine HOXA9; urinary bladder neoplasms; drug resistance; neoadjuvant therapy; decitabine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Xylinas, E.; Hassler, M.R.; Zhuang, D.; Krzywinski, M.; Erdem, Z.; Robinson, B.D.; Elemento, O.; Clozel, T.; Shariat, S.F. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. Biomolecules 2016, 6, 37.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top